Actualités Direxion Daily Healthcare Bull 3X Shares - CURE | Actions American Stock Exchange

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Curetis Elects Share Settlement for Excess Entitlement Under First Tranche of Yorkville Convertible Notes

- Share issue cap of 2.75 million shares under the first tranche of EUR 5 million in Yorkville convertible...

Curetis and AKO MED Ink Distribution Agreement Covering Four Countries in CEE Region

- AKO MED to exclusively distribute Unyvero A50 portfolio in Serbia, North Macedonia, Bosnia Hercegovina, and Montenegro - Preparing inclusion...

Curetis to Present at Solebury Trout European Biotech Investor Day in NYC

Amsterdam, the Netherlands, San Diego, CA, USA, and Holzgerlingen, Germany, July 25, 2019, 08:00 am CEST - Curetis N.V. (the "Company" and...

Curetis Files for U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens

- Final LRT BAL panel demonstrates overall weighted average sensitivity of up to 94.7% and overall weighted average specificity of up to 98.4...

Curetis Group Company Ares Genetics is Granted Key European Patent on Genetic Resistance Testing

Curetis Group Company Ares Genetics is Granted Key European Patent on Genetic Resistance Testing Patent broadly covers genetic biomarkers and...

Curetis To Attend Key Conferences in the Third Quarter of 2019

Amsterdam, the Netherlands, and Holzgerlingen, Germany, July 2, 2019, 08:00 am CET - Curetis N.V. (the "Company" and, together with its...

Curetis Reports Results of the Annual General Meeting Held on June 27, 2019

- All proposed AGM resolutions approved by shareholders Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, June 28...

New Data on Curetis’ Unyvero LRT Panel for Pneumonia to be Presented at ASM Microbe 2019

- Several scientific conference contributions outline benefits of U.S. FDA-cleared Unyvero LRT Application Cartridge in both endotracheal...

Curetis Reports Positive Results from Clinical Validation Study for U.S. FDA 510(k) Submission of Unyvero LRT for BAL Samples...

- Test shows overall weighted average sensitivity of 90.1% (94.7%) and overall weighted average specificity of 98.4% (97.9%) in prospective...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Direxion Daily Healthcare Bull 3X Shares (CURE)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

CURE Actualités

Curetis Elects Share Settlement for Excess Entitlement Under First Tranche of Yorkville Convertible Notes

Curetis and AKO MED Ink Distribution Agreement Covering Four Countries in CEE Region

Curetis to Present at Solebury Trout European Biotech Investor Day in NYC

Curetis Files for U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens

Curetis Group Company Ares Genetics is Granted Key European Patent on Genetic Resistance Testing

Curetis To Attend Key Conferences in the Third Quarter of 2019

Curetis Reports Results of the Annual General Meeting Held on June 27, 2019

New Data on Curetis’ Unyvero LRT Panel for Pneumonia to be Presented at ASM Microbe 2019

Curetis Reports Positive Results from Clinical Validation Study for U.S. FDA 510(k) Submission of Unyvero LRT for BAL Samples...

Curetis to Receive Additional EUR 6.5 Million Financing from EIB and Yorkville

Curetis Announces Financial Results for the First Three Months of 2019

Curetis to Hold Annual General Shareholders’ Meeting on June 27, 2019

Standard & Poor's Announces Changes to U.S. Indices

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Direxion Daily Healthcare Bull 3X Shares (CURE) Actualités

Direxion Daily Healthcare Bull 3X Shares (CURE)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

CURE Actualités

Curetis Elects Share Settlement for Excess Entitlement Under First Tranche of Yorkville Convertible Notes

Curetis and AKO MED Ink Distribution Agreement Covering Four Countries in CEE Region

Curetis to Present at Solebury Trout European Biotech Investor Day in NYC

Curetis Files for U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens

Curetis Group Company Ares Genetics is Granted Key European Patent on Genetic Resistance Testing

Curetis To Attend Key Conferences in the Third Quarter of 2019

Curetis Reports Results of the Annual General Meeting Held on June 27, 2019

New Data on Curetis’ Unyvero LRT Panel for Pneumonia to be Presented at ASM Microbe 2019

Curetis Reports Positive Results from Clinical Validation Study for U.S. FDA 510(k) Submission of Unyvero LRT for BAL Samples...

Curetis to Receive Additional EUR 6.5 Million Financing from EIB and Yorkville

Curetis Announces Financial Results for the First Three Months of 2019

Curetis to Hold Annual General Shareholders’ Meeting on June 27, 2019

Standard & Poor's Announces Changes to U.S. Indices

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application